Novo Nordisk Faces Critical Market Test with Q4 Results

All eyes are on Danish pharmaceutical giant Novo Nordisk this week as it prepares to release its fourth-quarter 2025 financial results. The report, due Wednesday, arrives at a pivotal moment marked by intensifying competition in the lucrative GLP-1 drug market and the recent U.S. launch of a key new product.

Earnings Release and Market Expectations

The company will publish its Q4 2025 figures on February 4, 2026, prior to the opening of the Copenhagen market. A conference call and live webcast for investors will follow at 13:00 CET.

Market consensus, as compiled by Zacks, anticipates quarterly revenue of $11.96 billion and earnings per share (EPS) of $0.89. A year-over-year decline in the projected EPS figure raises the stakes for the company’s forward-looking guidance, placing additional pressure on management’s commentary.

Oral Wegovy’s U.S. Debut Under Scrutiny

A primary focus will be the early performance of the oral Wegovy tablet in the United States. Having received FDA approval in December 2025, the treatment has been widely available since early January 2026. Karen Andersen, an analyst at Morningstar, noted that early prescription data from the initial weeks appeared “really good.”

Investors will be listening closely for management’s insights on the commercial momentum, especially within the direct-to-patient channel. A strong launch is one thing, but the market will be assessing the potential for sustained, scalable sales growth.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Mounting Headwinds: Competition and Pricing Pressures

The ongoing rivalry with Eli Lilly remains a dominant theme in the GLP-1 sector. Lilly’s products, Mounjaro and Zepbound, continue to capture market share from Novo Nordisk’s Ozempic and Wegovy. For the first nine months of 2025, Zacks estimates the combined revenue of Lilly’s tirzepatide products at $24.8 billion, underscoring the fierce competitive landscape.

Compounding this challenge is pricing pressure. Morningstar forecasts a revenue decline of approximately 2% for Novo Nordisk in 2026. This projection is partly based on a pricing agreement with the U.S. government reached in November 2025, designed to expand access to GLP-1 medications. The agreement is expected to lead to noticeable price reductions for semaglutide products in the U.S. market during 2026.

Pipeline Developments and Recent Volatility

Beyond the financials, operational updates are also anticipated. The company expanded its collaboration with Aspect Biosystems on January 20, 2026, aiming to develop cell-based therapies for diabetes. Furthermore, Novo Nordisk submitted a higher Wegovy injection dose (7.2 mg) to the FDA in late November 2025; the European Medicines Agency recommended this dosage in December 2025.

Recent trading activity reflects investor unease, with the share price declining by 6.92% over the past seven sessions.

Consequently, the events of February 4 will be decisive. The key question is whether Novo Nordisk can reassure the market with robust commentary on the tablet launch, its competitive positioning, and the 2026 pricing outlook—or if its guidance will instead temper expectations.